-
- Seiji Mabuchi
- Department of Obstetrics and Gynecology, Nara Medical University, Nara 634-8522, Japan
-
- Tomoyuki Sasano
- Department of Obstetrics and Gynecology, Osaka Saiseikai Nakatsu Hospital, Osaka 530-0012, Japan
-
- Naoko Komura
- Department of Obstetrics and Gynecology, Kaizuka City Hospital, Osaka 597-0015, Japan
書誌事項
- 公開日
- 2021-02-05
- 資源種別
- journal article
- 権利情報
-
- https://creativecommons.org/licenses/by/4.0/
- DOI
-
- 10.3390/cells10020329
- 公開者
- MDPI AG
説明
<jats:p>Myeloid-derived suppressor cells (MDSCs) are a heterogeneous population of immature myeloid cells that exhibit immunosuppressive activity. They also directly stimulate tumor cell proliferation, metastasis, and angiogenesis. In ovarian cancer, there are increased numbers of circulating or tumor-infiltrating MDSCs, and increased frequencies of MDSCs are associated with a poor prognosis or an advanced clinical stage. Moreover, in murine models of ovarian cancer, MDSC depletion has shown significant growth-inhibitory effects and enhanced the therapeutic efficacy of existing anticancer therapies. In this review, we summarize the current knowledge on MDSC biology, clinical significance of MDSC, and potential MDSC-targeting strategies in ovarian cancer.</jats:p>
収録刊行物
-
- Cells
-
Cells 10 (2), 329-, 2021-02-05
MDPI AG
